Risk Factors Update Summary

• Development and commercialization risks increased due to termination of Patent License with NCI.
• Strategic reprioritization announced, reducing workforce by approximately 95% to extend cash runway.
• Cash and cash equivalents decreased from approximately $53 million in 2022 to $6 million in 2023.
• Potential negative impact on clinical programs due to inability to regain terminated rights.
• Exploration of strategic alternatives ongoing, engaging Cantor Fitzgerald & Co. as strategic advisor.
• Implemented Plan included reducing workforce, discontinuing clinical development programs, and prioritizing resources.
• Risks heightened by reliance on limited vendors for reagents and equipment in manufacturing.
• Net loss decreased from $37 million in 2022 to $35 million in 2023.
• Incurred $1.5 million for retention, severance, and termination costs from Q3 2023 to Q4 2023.
• Uncertainty in ability to submit BLA to FDA and generate significant revenues.
• Accumulated deficit increased from $880 million in 2022 to $915 million in 2023.
• Risks associated with potential side effects and adverse reactions of product candidates.
• Challenges in patient enrollment and completion of clinical trials may delay development.
• Risks related to cybersecurity incidents and breaches impacting sensitive information.